The knockdown of METTL3 significantly decreased PD‐L1 and CD47 expressions, which indicates that m6A‐mediated upregulation of TUG1 is closely related to tumor immunity and may mediate tumor immune escape by regulating immune checkpoints, which can serve as novel immunotherapeutic strategies for clinical patients suffering from HCC. Here, METTL3 is linked to hepatocellular carcinoma.